CEVEC strengthens its Scientific Advisory Board with the appointment of gene therapy specialist J. Fraser Wright, Ph.D.
- Wright is a widely recognized worldwide expert in the fields of gene therapy and adeno associated viral (AAV) vectors with more than 20 years of experience in industry and academic settings
- Wright’s appointment completes CEVEC’s CAP®GT Scientific Advisory Board, implemented to support CEVEC in its goal establishing CAP®GT as the industry standard for scalable production of viral gene therapy vectors
Cologne, Germany, June 28, 2018
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors today announced the appointment of J. Fraser Wright, Ph.D., Chief Technology Officer, Gene Therapies at Axovant and Scientific Co-Founder and former CTO at Spark Therapeutics as new member of its CAP-GT Scientific Advisory Board.